hit counter
Antares Pharma, Inc. (ATRS) Stock News Sentiment & Price - Sentifly
ATRS - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Antares Pharma, Inc. (ATRS)

USA
Medical Instruments & Supplies
NASDAQ
ATRS Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ATRS Latest news
Seeking Alpha
Neutral
Antares Pharma, Inc. (ATRS) CEO Robert Apple on Q3 2021 Results - Earnings Call Transcript
2021-11-04 17:24

Antares Pharma, Inc. (ATRS) CEO Robert Apple on Q3 2021 Results - Earnings Call Transcript

Zacks Investment Research
Positive
Antares Pharma (ATRS) Q3 Earnings Match Estimates
2021-11-04 09:57

Antares Pharma (ATRS) delivered earnings and revenue surprises of 0.00% and -0.69%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire
Neutral
Antares Pharma Reports Third Quarter 2021 Financial and Operating Results
2021-11-04 07:00

Increased Revenue 20% Year-Over-Year to $48.2 Million

Zacks Investment Research
Neutral
Antares Pharma (ATRS) Reports Next Week: What to Expect
2021-10-28 16:51

Antares Pharma (ATRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire
Neutral
Antares Pharma Announces Oral Presentation at the 22nd Annual Fall Scientific Meeting of SMSNA
2021-10-25 08:30

EWING, N.J., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that an abstract on XYOSTED®, a subcutaneous testosterone enanthate injection, was accepted as on oral presentation at the 22nd Annual Fall Scientific Meeting of SMSNA in Scottsdale, AZ on October 21-24, 2021.

GlobeNewsWire
Neutral
Antares Pharma to Report Third Quarter 2021 Financial and Operating Results
2021-10-21 08:30

EWING, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced it will release its third quarter 2021 financial and operating results on Thursday, November 4, 2021, before the market opens.

GlobeNewsWire
Neutral
Antares Pharma Initiates Phase I Study For ATRS-1902 For Adrenal Crisis Rescue
2021-09-30 09:00

Pharmacokinetic data results expected in 1Q 2022 Pharmacokinetic data results expected in 1Q 2022

GlobeNewsWire
Neutral
Antares Pharma to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
2021-09-08 08:30

EWING, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, will participate and host investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference being held on September 13-15, 2021.

The Motley Fool
Positive
Got $1,000? These 2 Bargain-Bin Biopharma Stocks Might Be Worth Buying
2021-08-27 10:15

These healthcare stocks have their warts, but the price is right for long-term investors.

Seeking Alpha
Neutral
Antares Pharma's (ATRS) CEO Robert Apple on Q2 2021 Results - Earnings Call Transcript
2021-08-05 15:15

Antares Pharma's (ATRS) CEO Robert Apple on Q2 2021 Results - Earnings Call Transcript

Loading more news...